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Premature Babies: The Art and The SciencesPatent ductus arteriosus (PDA) is the most common car-
diovascular abnormality in premature infants, with the
incidence depending on the estimated gestational age.
Although ductus arteriosus is important for prenatal and
immediate postnatal circulation, its persistence beyond the
transitional period is associated with neonatal morbidity
and mortality.1 There is no consensus among neonatologists
on the management of PDA; the reason for this variation is
that current evidence does not mandate one treatment
over any other. Therefore, “to treat or not to treat, when
to treat and how to treat” are still the main questions.2
To answer these questions, the best way is to establish
treatment criteria. Some scholars have used clinical param-
eters to sum up a cardiovascular dysfunction score,3 and
others have used serum biomarkers such as B-type natriuretic
peptide to predict the course of PDA,4 whereas most re-
searchers have preferred to apply echocardiography evalua-
tion to quantify the impact of significant PDA. There aremany
echocardiographic criteria, such as increased left atrium to
ascending aorta diameter ratio, increased end diastolic flow
of the left pulmonary artery, left ventricular output (LVO) to
right ventricular output (RVO) ratio (LVO/RVO), LVO to supe-
rior vena cava flow ratio, PDA size or its flow, and PDA/left
pulmonary artery ratio.5 However, the indications for the
treatment of premature very low birth weight infants
(VLBWIs) with PDA have not been well established.
In the current issue of this Journal, Nagasawa et al
report6 their experience using the value of the measured
left ventricular end-diastolic dimension (LVDd), which was
divided by the normal LVDd as an index (LVDd ratio), to
compare 30 patients who underwent PDA ligation to 30
patients treated with indomethacin and 30 patients who did
not undergo radical therapy. They found that the per-
centage of patients with <115% in the LVDd ratio was 90% in
the no-radical-therapy patients. The LVDd ratios of 130%
and 115% were regarded as cut-off values for surgical liga-
tion and indomethacin treatment. Therefore, the LVDd
ratio can be considered a useful measure to determine the
treatment of VLBWIs with PDA.
Theoretically, it is very reasonable that the LVDd in PDA
patients is commonly increased because of its extendedhttp://dx.doi.org/10.1016/j.pedneo.2014.04.003
1875-9572/Copyright ª 2014, Taiwan Pediatric Association. Published bpulmonary flow, as a consequence of the flow volume
through the ductus arteriosus. Therefore, LVDd measure-
ment could be a useful criterion for determining treatment
in VLBWIs with PDA. However, due to different gestational
ages and body weights, the size of LVDd varies. Therefore,
the authors needed to establish a normal value for LVDd
and used the LVDd ratio to set up the criteria.7 Before we
adopt these novel criteria, there are some concerns with
regard to applying the results of this study. The first one
would be that this study was a retrospective design. Even if
the inter- or intraobserver error was low, selection bias
might still exist. As mentioned in the article,6 the treat-
ment choice did not depend on the LVDd ratio, the sex and
appropriate for gestational age/large for gestational age
distributions were not similar between groups, and differ-
ences existed on the examination day. The second concern
is that the authors collected the cases over a 13-year period
(from February 1999 to February 2012); therefore, it is
necessary to convince others that technical or advanced
concepts did not change the clinical neonatal care practice
over the decade.
Although these minor concerns exist, the authors pro-
vide many solid data to explain the results. In the future,
we believe that a multicenter study, or a prospective
randomized study using the LVDd ratio, may help to prove
that ratio as a useful measure to determine the treatment
of VLBWIs with PDA.
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